KBA-1331

N/A

Report date: 2023/12/21 17:45:40

Base Information

Drug NameKBA-1331
Drug Alias NameKBA-1331KBA1331
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAnti-U5 small nuclear ribonucleoprotein 200 kDa helicase
TargetsU5 small nuclear ribonucleoprotein 200 kDa helicase
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKling Biotherapeutics BV
China Registration ClassN/A

Develop Information

Active CompaniesKling Biotherapeutics BV
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A